Cytokinetics (CYTK) Non-Current Deffered Revenue (2011 - 2022)
Cytokinetics (CYTK) posted quarterly Non-Current Deffered Revenue of $87.0 million for Q3 2022, little changed year-over-year from $87.0 million in Q3 2021, and little changed quarter-over-quarter from $87.0 million in Q1 2022.
Cytokinetics (CYTK) Non-Current Deffered Revenue (2011 - 2022) Analysis & Trends
Cytokinetics (CYTK) has reported Non-Current Deffered Revenue for 10 consecutive years, with $87.0 million the latest figure, recorded in Q3 2022.
- In Q3 2022, Non-Current Deffered Revenue changed 0.0% year-over-year to $87.0 million; the TTM figure through Sep 2022 stood at $87.0 million (changed 0.0% YoY), while the FY2021 annual figure was $87.0 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue was little changed at $87.0 million in Q3 2022 per CYTK's latest filing, from $87.0 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $87.0 million in Q4 2020 and bottomed at $87.0 million in Q4 2020.
- Historically, Non-Current Deffered Revenue has averaged $87.0 million across 3 years, with a median of $87.0 million in 2020.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 0.0% in 2021 and fell as far as 0.0% in 2021.
- Cytokinetics' Non-Current Deffered Revenue stood at $87.0 million in 2020, then changed by 0.0% to $87.0 million in 2021, then changed by 0.0% to $87.0 million in 2022.
- Business Quant data shows CYTK's Non-Current Deffered Revenue at $87.0 million in Q3 2022, $87.0 million in Q1 2022, and $87.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 87.00 Mn |
| Mar 31, 2022 | 87.00 Mn |
| Dec 31, 2021 | 87.00 Mn |
| Sep 30, 2021 | 87.00 Mn |
| Jun 30, 2021 | 87.00 Mn |
| Mar 31, 2021 | 87.00 Mn |
| Dec 31, 2020 | 87.00 Mn |
| Dec 31, 2017 | 15.00 Mn |
| Sep 30, 2017 | 15.87 Mn |
| Jun 30, 2017 | 15.07 Mn |
| Mar 31, 2017 | 72,000.00 |
| Dec 31, 2016 | 15.00 Mn |
| Sep 30, 2016 | 15.64 Mn |
| Jun 30, 2016 | 1.28 Mn |
| Mar 31, 2016 | 312,000.00 |
| Dec 31, 2015 | 359,000.00 |
| Sep 30, 2015 | 4.35 Mn |
| Jun 30, 2015 | 8.29 Mn |
| Mar 31, 2015 | 12.21 Mn |
| Dec 31, 2014 | 16.56 Mn |